Amgen Inc (AMGN) stock
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3022% above fair value
$465.67−1.39 (-0.30%)
Close on Nov 13, 2026Market cap $251.76BP/E 27.0Yield 2.07%
Amgen enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Amgen's enterprise value was $296.38B on Nov 11, 2026, against $231.17B a year earlier. Over the last 5 years it ranged from $147.93B to $296.38B, with a median of $200.34B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $296.38B | +33.9% |
| 2025 | Dec 31, 2025 | $221.40B | +15.6% |
| 2024 | Dec 31, 2024 | $191.48B | +6.5% |
| 2023 | Dec 29, 2023 | $179.85B | +7.5% |
| 2022 | Dec 30, 2022 | $167.34B | +10.3% |
| 2021 | Dec 31, 2021 | $151.77B | -2.8% |
| 2020 | Dec 31, 2020 | $156.09B | +1.4% |
| 2019 | Dec 31, 2019 | $154.00B | +17.7% |
| 2018 | Dec 31, 2018 | $130.85B | -17.8% |
| 2017 | Dec 29, 2017 | $159.13B | +13.1% |
| 2016 | Dec 30, 2016 | $140.74B | -6.8% |
| 2015 | Dec 31, 2015 | $151.08B | +0.4% |
| 2014 | Dec 31, 2014 | $150.46B | +43.4% |
| 2013 | Dec 31, 2013 | $104.92B | +24.3% |
| 2012 | Dec 31, 2012 | $84.41B | +21.5% |
| 2011 | Dec 30, 2011 | $69.47B | +15.5% |
| 2010 | Dec 31, 2010 | $60.15B | +0.3% |
| 2009 | Dec 31, 2009 | $59.99B | – |
See a number that looks wrong?